Status:

COMPLETED

To Decrease Fatigue With Light Therapy

Lead Sponsor:

The Netherlands Cancer Institute

Collaborating Sponsors:

Dutch Cancer Society

Conditions:

Hodgkin Lymphoma

Diffuse Large B Cell Lymphoma

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

Cancer related fatigue (CRF) is one of the most prevalent and distressing long-term complaints reported by (non-) Hodgkin survivors. The SPARKLE study will test the efficacy of two intensities of ligh...

Detailed Description

Rationale: Cancer related fatigue (CRF) is one of the most prevalent and distressing long-term complaints reported by (non-)Hodgkin survivors. So far, there is no standard treatment. Some non-pharmaco...

Eligibility Criteria

Inclusion

  • A history of Hodgkin or DLBCL with a survivorship of ≥ 3 years.
  • The presence of moderate to severe fatigue symptoms since diagnosis of or treatment for Hodgkin lymphoma or DLBCL.

Exclusion

  • Fatigue is explained by a somatic factor as defined in the guidelines of chronic fatigue syndrome of the Dutch internists association (NIV). When a somatic cause for fatigue is resolved by stable medication use ≥ 6 months, patients can be included in the current trial.
  • Pregnancy (until 3 months postnatal) or women who provide breast feeding
  • Extensive surgical operations in the past 3 months.
  • Current diagnosis of a psychiatric disorder (e.g. personality disorders, psychosis, bipolar disorder) which would limit participation.
  • Diagnosis of and treatment for a secondary malignancy in the past 12 months.
  • Presence of photophobia (abnormal intolerance to visual perception of light) or another eye disease that shows symptoms of photophobia (e.g. aniridia, retinitis pigmentosa, glaucoma).
  • Current or previous use of light therapy for more than 1 week.
  • Current employment in shift work.
  • Insufficient knowledge of the Dutch language.

Key Trial Info

Start Date :

September 20 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 11 2020

Estimated Enrollment :

166 Patients enrolled

Trial Details

Trial ID

NCT03242902

Start Date

September 20 2017

End Date

August 11 2020

Last Update

September 1 2020

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Radboudumc

Nijmegen, Gelderland, Netherlands, 6500 HB

2

Netherlands Cancer Institute

Amsterdam, North Holland, Netherlands, 1066 CX

3

VUmc

Amsterdam, North Holland, Netherlands, 1081 HV

4

Leids Universitair Medisch Centrum

Leiden, South Holland, Netherlands, 2300 RC